ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) was the target of a significant drop in short interest during the month of June. As of June 30th, there was short interest totalling 52,400 shares, a drop of 67.6% from the May 30th total of 161,900 shares. Based on an average trading volume of 770,600 shares, the short-interest ratio is presently 0.1 days. Approximately 0.3% of the shares of the company are sold short.

A number of equities analysts recently weighed in on CTRV shares. ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Maxim Group reiterated a “buy” rating and issued a $3.00 price objective on shares of Actinium Pharmaceuticals in a research report on Wednesday, March 20th.

NASDAQ:CTRV traded down $0.08 during midday trading on Thursday, reaching $4.04. The stock had a trading volume of 270,710 shares, compared to its average volume of 383,772. The business’s fifty day simple moving average is $4.48. ContraVir Pharmaceuticals has a 12-month low of $3.52 and a 12-month high of $91.00.

ContraVir Pharmaceuticals (NASDAQ:CTRV) last posted its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($7.69) earnings per share for the quarter.

A hedge fund recently raised its stake in ContraVir Pharmaceuticals stock. Barclays PLC boosted its position in ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 229.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 179,480 shares of the biopharmaceutical company’s stock after buying an additional 124,958 shares during the period. Barclays PLC owned approximately 1.08% of ContraVir Pharmaceuticals worth $50,000 as of its most recent SEC filing. 1.07% of the stock is owned by institutional investors and hedge funds.

About ContraVir Pharmaceuticals

ContraVir Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection.

Recommended Story: Consumer Price Index (CPI)

Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with's FREE daily email newsletter.